Research programme: antibody therapeutics - Antitope/Synthon Biopharmaceuticals
Latest Information Update: 06 Sep 2014
At a glance
- Originator Antitope; Synthon
- Developer Antitope
- Class Antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Unspecified
Most Recent Events
- 02 Sep 2014 Early research in Undefined indication in Netherlands (unspecified route)
- 02 Sep 2014 Early research in Undefined indication in United Kingdom (unspecified route)